Alternatively, an optimized GBM CTC enrichment protocol may allow to successfully detect EGFRvIII transcripts in CTC samples, comparable to androgen receptor variant 7 (AR-V7) analysis in prostate cancer [53]. This evidence concerns the gene AR and prostate carcinoma.